Pharma Deals Review, Vol 2010, No 9 (2010)

Font Size:  Small  Medium  Large

MacroGenics Signs Deals with Boehringer Ingelheim and Pfizer for DART™ Targets

Editorial Team

Abstract


MacroGenics Inc has announced two antibody discovery deals using its DART™ technology platform. The first with Boehringer Ingelheim has a potential value of USD 2.16 B and covers multiple diseases, while the second is for two cancer targets with Pfizer.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.